{"entity":{"id":"nct05879822","kind":"trial","name":"A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive","aka":[],"tldr":"A phase 2 trial of INCB099280 in advanced solid tumours, run by Incyte Corporation, active and no longer recruiting.","summary":"A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive is a phase 2 interventional study registered as NCT05879822 by Incyte Corporation, with 73 participants enrolled, started 2023-10-30 and due to reach its primary completion in 2026-09-30. Interventions recorded: INCB099280.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05879822","url":"https://clinicaltrials.gov/study/NCT05879822"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["incyte"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05879822","phase":"2","setting":"A Phase 2 Study Evaluating INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive","sponsor":"Incyte Corporation","enrolled":73,"outcomes":[]},"route":"/trials/nct05879822/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"incyte","kind":"company","name":"Incyte","route":"/companies/incyte/"}]}}